NCT03280667 - Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

June 4, 2023

Study Completion Date

June 4, 2023

Conditions

Renal Cell Carcinoma, Clear CellMetastatic Kidney Cancer

Interventions

DRUG

Pembrolizumab plus denosumab

Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D

Trial Locations (16)

St Vincent's Hospital Sydney, Sydney

Northern Cancer Institute, Frenchs Forest

St George, Sydney

Calvary Mater Newcastle, Newcastle

Border Medical Oncology Research Unit, Albury

Box Hill, Box Hill

Royal Brisbane and Womens hospital, Herston

Sunshine Coast University Hospital, Birtinya

Townsville Hospital, Townsville

Fiona Stanley Hospital, Perth

Concord Repatriation General Hospital, Sydney

Icon Cancer Care, Brisbane

Flinders Medical Centre, Adelaide

Monash Health, Melbourne

Peter MacCallum Cancer Center, Melbourne

Ballarat Oncology & Haematology Services, Wendouree